RAC isn't targeting the niche third line DLBCL market so IMU really has no bearing on RAC's commercial success.
The success/failure of IMU will have far reaching impacts on the ASX bio sector though, especially considering there's already >20k shareholders currently under water.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.2¢ | $304.8K | 23.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 57 | 13718532 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 5374446 | 13 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |